The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease
Open accessAbstract
Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant morbidity and mortality. Although first-line treatment of cGVHD is based on controlled trials, second-line treatment is almost solely based on phase II trials or retrospective analyses. The consensus conference on clinical practice in cGVHD held in Regensburg aimed to achieve a consensus on the current evidence of treatment options as well as to provide guidelines for daily clinical practice. Treatment modalities are the use of steroids and calcineurin inhibitors as well as immunomodulating modalities (photopheresis, mTOR-inhibitors, thalidomide, hydroxychloroquine, vitamin A analogs, clofazimine), and cytostatic agents (mycophenolate mofetil, methotrexate, cyclophosphamide, pentostatin). Recent reports showed some efficacy of rituximab, alemtuzumab, and etanercept in selected patients. Moreover, tyrosine kinase inihibitors such as imatinib came into the field because of their ability to interfere with the platelet-derived growth factor (PDGF-R) pathway involved in fibrosis. An other treatment option is low-dose thoracoabdominal irradiation. Although different treatment options are available, the "trial-and-error system" remains the only way to identify the drug effective in the individual patient, and valid biomarkers are eagerly needed to identify the likelihood of response to a drug in advance. Moreover, the sparse evidence for most treatment entities indicates the urgent need for systematic evaluation of second-line treatment options in cGVHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G.-S., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.12.001 · Cited by 5,459
Self-citationFilipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., et al. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.09.004 · Cited by 3,556
Self-citationCyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
de Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Regulation of PDGF and its receptors in fibrotic diseases
Bonner, J. C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.006 · Cited by 768
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, M. A., Vilcek, J., Daddona, P., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 703
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Pavletic, S. Z., Martin, P., Lee, S. J., Mitchell, S., Jacobsohn, D., Cowen, E. W., Turner, M. L., Akpek, G., Gilman, A., McDonald, G., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.01.008 · Cited by 563
Self-citationXiao, S., Jin, H., Korn, T., Liu, S. M., Oukka, M., Lim, B., & Kuchroo, V. K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2277 · Cited by 537
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
Zeiser, R., Nguyen, V. H., Beilhack, A., Buess, M., Schulz, S., Baker, J., Contag, C. H., & Negrin, R. S. (2006) · Blood · doi:10.1182/blood-2006-01-0329 · Cited by 504
Imatinib for the Treatment of Pulmonary Arterial Hypertension
Ghofrani, H. A., Seeger, W., & Grimminger, F. (2005) · New England Journal of Medicine · doi:10.1056/nejmc051946 · Cited by 492
Shulman, H. M., Kleiner, D., Lee, S. J., Morton, T., Pavletic, S. Z., Farmer, E., Moresi, J. M., Greenson, J., Janin, A., Martin, P. J., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.10.023 · Cited by 487
Self-citationInhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Rituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C., et al. (2006) · Blood · doi:10.1182/blood-2006-01-0233 · Cited by 452
Greinix, H. T., Volc-Platzer, B., Rabitsch, W., Gmeinhart, B., Guevara-Pineda, C., Kalhs, P., Krutmann, J., Hönigsmann, H., Ciovica, M., & Knobler, R. M. (1998) · Blood · doi:10.1182/blood.v92.9.3098 · Cited by 328
Self-citationCouriel, D., Carpenter, P. A., Cutler, C., Bolaños-Meade, J., Treister, N. S., Gea-Banacloche, J., Shaughnessy, P., Hymes, S., Kim, S., Wayne, A. S., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.02.003 · Cited by 321
Self-citationAntileukemic activity of rapamycin in acute myeloid leukemia
Récher, C., Beyne-Rauzy, O., Demur, C., Chicanne, G., Dos Santos, C., Mas, V. M.-D., Benzaquen, D., Laurent, G., Huguet, F., & Payrastre, B. (2005) · Blood · doi:10.1182/blood-2004-06-2494 · Cited by 296
Peleg, A. Y., Husain, S., Kwak, E. J., Silveira, F. P., Ndirangu, M., Tran, J., Shutt, K. A., Shapiro, R., Thai, N., Abu-Elmagd, K. M., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/510388 · Cited by 265
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
Furst, D. E. (1996) · Lupus · doi:10.1177/0961203396005001041 · Cited by 233
Imatinib for refractory chronic graft-versus-host disease with fibrotic features
Olivieri, A., Locatelli, F., Zecca, M., Sanna, A., Cimminiello, M., Raimondi, R., Gini, G., Mordini, N., Balduzzi, A., Leoni, P., et al. (2009) · Blood · doi:10.1182/blood-2009-02-204156 · Cited by 231
Johnston, A., Gudjonsson, J. E., Sigmundsdottir, H., Runar Ludviksson, B., & Valdimarsson, H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.09.001 · Cited by 231
Greinix, H. T., Volc-Platzer, B., Kalhs, P., Fischer, G., Rosenmayr, A., Keil, F., Hönigsmann, H., & Knobler, R. M. (2000) · Blood · doi:10.1182/blood.v96.7.2426 · Cited by 228
Self-citationParfitt, J. R., Jayakumar, S., & Driman, D. K. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31816bf3fe · Cited by 228
Gatza, E., Rogers, C. E., Clouthier, S. G., Lowler, K. P., Tawara, I., Liu, C., Reddy, P., & Ferrara, J. L. M. (2008) · Blood · doi:10.1182/blood-2007-11-125542 · Cited by 215
Retinoic Acid Can Directly Promote TGF-β-Mediated Foxp3+ Treg Cell Conversion of Naive T Cells
Mucida, D., Pino-Lagos, K., Kim, G., Nowak, E., Benson, M. J., Kronenberg, M., Noelle, R. J., & Cheroutre, H. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.008 · Cited by 191
Thalidomide as salvage therapy for chronic graft-versus-host disease
Parker, P., Chao, N., Nademanee, A., O'Donnell, M., Schmidt, G., Snyder, D., Stein, A., Smith, E., Molina, A., & Stepan, D. (1995) · Blood · doi:10.1182/blood.v86.9.3604.bloodjournal8693604 · Cited by 190
Couriel, D. R., Saliba, R., Escalón, M. P., Hsu, Y., Ghosh, S., Ippoliti, C., Hicks, K., Donato, M., Giralt, S., Khouri, I. F., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05616.x · Cited by 185
SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1
Benito, A. I., Furlong, T., Martin, P. J., Anasetti, C., Appelbaum, F. R., Doney, K., Nash, R. A., Papayannopoulou, T., Storb, R., Sullivan, K. M., et al. (2001) · Transplantation · doi:10.1097/00007890-200112270-00010 · Cited by 184
Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease
Gorgun, G., Miller, K. B., & Foss, F. M. (2002) · Blood · doi:10.1182/blood-2002-01-0068 · Cited by 181
Treatment of refractory chronic GVHD with rituximab: a GITMO study
Zaja, F., Bacigalupo, A., Patriarca, F., Stanzani, M., Van Lint, M. T., Filì, C., Scimè, R., Milone, G., Falda, M., Vener, C., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705725 · Cited by 170
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
Martin, P. J., Storer, B. E., Rowley, S. D., et al. (2009) · Blood · doi:10.1182/blood-2009-02-202937 · Cited by 166
Chronic graft versus host disease
Higman, M. A., & Vogelsang, G. B. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04945.x · Cited by 162
Self-citationKuppahally, S., Al-Khaldi, A., Weisshaar, D., Valantine, H. A., Oyer, P., Robbins, R. C., & Hunt, S. A. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01282.x · Cited by 160
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease
Magro, L., Mohty, M., Catteau, B., Coiteux, V., Chevallier, P., Terriou, L., Jouet, J., & Yakoub‐Agha, I. (2009) · Blood · doi:10.1182/blood-2009-02-204750 · Cited by 134
Self-citationRapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Johnston, L., Brown, J. W., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., Negrin, R. S., & Chao, N. J. A. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.10.004 · Cited by 131
Kharfan‐Dabaja, M. A., Mhaskar, A., Djulbegović, B., Cutler, C. S., Mohty, M., & Kumar, A. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.04.003 · Cited by 129
Self-citationSeaton, E. D., Szydlo, R., Kanfer, E., Apperley, J. F., & Russell‐Jones, R. (2003) · Blood · doi:10.1182/blood-2002-11-3351 · Cited by 120
Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation
Marty, F. M., Lowry, C. M., Cutler, C. S., Campbell, B., Fiumara, K., Baden, L. R., & Antin, J. H. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.12.032 · Cited by 112
Chiang, K., Abhyankar, S., Bridges, K. D., Godder, K. T., & Henslee-Downey, J. P. (2002) · Transplantation · doi:10.1097/00007890-200202270-00035 · Cited by 111
Mitchell, S. A., Leidy, N. K., Mooney, K. H., Dudley, W. N., Beck, S. L., LaStayo, P. C., Cowen, E. W., Palit, P., Comis, L. E., Krumlauf, M., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.238 · Cited by 101
Self-citationThalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Lepper, E. R., Smith, N. F., Cox, M. C., Scripture, C. D., & Figg, W. D. (2006) · Current Drug Metabolism · doi:10.2174/138920006778017777 · Cited by 95
Potential Mechanisms of Photopheresis in Hematopoietic Stem Cell Transplantation
Peritt, D. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.11.005 · Cited by 89
Pérez‐Simón, J. A., Encinas, C., Silva, F., Arcos, M. J., Díez‐Campelo, M., Sanchez-Guijo, F. M., Colado, E., Martín, J., Vázquez, L., del Cañizo, C., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.07.015 · Cited by 88
Treatment of Chronic Graft-Versus-Host Disease With Clofazimine
Lee, S. J., Wegner, S. A., McGarigle, C. J., Bierer, B. E., & Antin, J. H. (1997) · Blood · doi:10.1182/blood.v89.7.2298 · Cited by 76
Molecular actions of sirolimus: sirolimus and mTor
Kirken, R. A., & Wang, Y. L. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00230-6 · Cited by 68
Fong, K., & Feng, P.-H. (1996) · Lupus · doi:10.1177/096120339600500104 · Cited by 66
Sirolimus as Part of Immunosuppressive Therapy for Refractory Chronic Graft-versus-Host Disease
Jurado, M., Vallejo, C. T., Pérez‐Simón, J. A., Brunet, S., Ferra, C. M., Balsalobre, P., de Oteyza, J. P., Espigado, I., Romero, A., Caballero, D. M., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.02.003 · Cited by 63
Extracorporeal photochemotherapy for the treatment of graft-versus-host disease.
Rossetti, F., Dall’Amico, R., Crovetti, G., Messina, C., Montini, G., Dini, G., Locatelli, F., Argiolu, F., MINIERO, R., & Zacchello, G. (1996) · PubMed · Cited by 59
Chapman, J. R., Valantine, H. A., Albanell, J., Arns, W., Campistol, J. M., Eisen, H. J., Frigerio, M., Lehmkuhl, H. B., Marcén, R., Morris, R. E., et al. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.09.008 · Cited by 58
Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD
Magro, L., Catteau, B., Coiteux, V., Bruno, B., Jouet, J. P., & Yakoub‐Agha, I. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.252 · Cited by 57
Infliximab for GVHD therapy in children
Sleight, B., Chan, K. W., Braun, T., Serrano, A., & Gilman, A. L. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705761 · Cited by 57
Schleuning, M., Judith, D., Jedlickova, Z., Stübig, T., Heshmat, M., Baurmann, H., & Schwerdtfeger, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.377 · Cited by 51
Self-citationUpdate on extracorporeal photochemotherapy for graft-versus-host disease treatment
Kanold, J., Messina, C., Halle, P., Locatelli, F., Lanino, E., Cesaro, S., Deméocq, F., & on behalf of the Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704851 · Cited by 50
Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J. G., Saso, R. M., Horton, C., Atra, A., Ortín, M., Rudin, C. M., Goyal, S. D., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704033 · Cited by 48
Daclizumab for children with corticosteroid refractory graft-versus-host disease
Teachey, D. T., Bickert, B. M., & Bunin, N. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705199 · Cited by 38
Steady-State Pharmacokinetics of Hydroxychloroquine in Rheumatoid Arthritis Patients
Miller, D. R., Khalil, S. K. W., & Nygard, G. A. (1991) · DICP · doi:10.1177/106002809102501202 · Cited by 36
Malladi, R. K., Peniket, A., Littlewood, T. J., Towlson, K. E., Pearce, R., Yin, J. A. L., Cavenagh, J. D., Craddock, C., Orchard, K. H., Olavarría, E., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.375 · Cited by 35
Imatinib as a Potential Treatment for Sclerodermatous Chronic Graft-vs-Host Disease
Moreno-Romero, J. A. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.9.1106 · Cited by 35
Pharmaceutical and Cellular Strategies in Prophylaxis and Treatment of Graft-Versus-Host Disease
Wolff, D., Steiner, B., Hildebrandt, G. C., Edinger, M., & Holler, E. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788453158 · Cited by 26
Self-citationIsotretinoin Therapy for Progressive Systemic Sclerosis
Bahmer, F. A. (1985) · Archives of Dermatology · doi:10.1001/archderm.1985.01660030028010 · Cited by 24
Auffermann-Gretzinger, S., Eger, L., Schetelig, J., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000260433.86776.ec · Cited by 14
Klink, A., Schilling, K., Rapp, K., Höffken, K., & Sayer, H. G. (2008) · Blood · doi:10.1182/blood.v112.11.2210.2210 · Cited by 9
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703472 · Cited by 748
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Imatinib: A Breakthrough of Targeted Therapy in Cancer
Iqbal, N., & Iqbal, N. (2014) · Chemotherapy Research and Practice · doi:10.1155/2014/357027 · Cited by 470
Metadata
- Authors
- Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F., Kiani, A., Schwerdtfeger, R., Vogelsang, G. B., Kobbe, G., Gramatzki, M., Lawitschka, A., Mohty, M., Pavletic, S. Z., Greinix, H., & Holler, E.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 17
- Issue
- 1
- Pages
- 1-17
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2031549987
- Cited by
- 327
- References
- 63
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.